Skip to content
Screener

Taysha Gene Therapies, Inc. TSHA Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$231.56M+41.3%
Biogen logo
BiogenBIIB
$245.7M-26.5%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$69.42M+36.1%
uniQure logo
uniQureQURE
$11.61M-14.9%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$2.57M+26.7%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$12.12M+91.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$47.3M-77.0%
Net income-$46.6M-73.5%
EPS (diluted)-$0.13-44.4%

Balance sheet

See full
Cash & equivalents$455.4M+45.6%
Total debt$56.7M-5.1%
Total equity$387.3M+55.7%
Total assets$470.4M+41.1%

Cash flow

See full
Operating cash flow-$40.4M-100%
CapEx$24.0K-93.7%
Free cash flow-$40.4M-100%

Valuation

See full
Market cap$1.83B+154%
Enterprise value$1.43B+205%
P/S333.7×+245×

Profitability

See full
Operating margin-2,792.3%-9,679pp
Net margin-2,728%-9,858pp
FCF margin-2,417%-8,925pp

Returns & leverage

See full
Return on equity-47.1%-4.0pp
Debt / equity0.1×-0.1×
Current ratio17.8×+5.3×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344610
Line itemJune 30,2026December 31,2025
Total current assets461,434324,647
Restricted cash1642,315
Property, plant and equipment, net2,4126,736
Operating lease right-of-use assets6,3179,439
Other non-current assets106183
Total assets$470,433$343,320
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:

Item 1. Financial Statements.

FAQ

What is Taysha Gene Therapies, Inc.'s operating lease ROU assets?
Taysha Gene Therapies, Inc. (TSHA) reported operating lease ROU assets of $6.32M in Q2 2026.
How has Taysha Gene Therapies, Inc.'s operating lease ROU assets changed year-over-year?
Taysha Gene Therapies, Inc.'s operating lease ROU assets decreased by 18.7% year-over-year, from $7.77M to $6.32M.
What is the long-term trend for Taysha Gene Therapies, Inc.'s operating lease ROU assets?
Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s operating lease ROU assets has grown at a -4.8% compound annual growth rate (CAGR), from $10.94M to $9.44M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Taysha Gene Therapies, Inc.'s operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude